| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,740,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Shattuck Labs is a clinical-stage biopharmaceutical company engaged in developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint and GADLEN™ platforms, as classes of biologic medicines capable of multifunctional activity with applications in oncology and inflammatory diseases. Co.'s product candidate SL-172154, which is in Phase 1 clinical trial for the treatment of patients with ovarian cancer. Co.'s second product candidate, SL-279252, which is developed to inhibit the PD-1/PD-L1 interaction and activate the OX40 costimulatory receptor and is in Phase 1 clinical trial in patients with solid tumors and lymphoma. Co. has several compounds in preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,612,254 |
12,612,254 |
12,745,625 |
12,804,941 |
| Total Buy Value |
$10,943,652 |
$10,943,652 |
$11,110,366 |
$11,237,365 |
| Total People Bought |
2 |
2 |
3 |
5 |
| Total Buy Transactions |
2 |
2 |
3 |
7 |
| Total Shares Sold |
0 |
0 |
133,371 |
174,375 |
| Total Sell Value |
$0 |
$0 |
$166,714 |
$585,236 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2025-07-20 |
2025-04-18 |
2024-10-18 |
2023-10-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ashiya Mona |
Director |
– • – |
2025-08-25 |
4 |
B |
$0.87 |
$5,471,826 |
I/I |
6,306,127 |
1,051,021 |
2.1 |
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2025-08-25 |
4 |
B |
$0.87 |
$5,471,826 |
I/I |
6,306,127 |
1,051,021 |
2.1 |
- |
|
| Neill Andrew R |
Chief Financial Officer |
• – – |
2025-08-25 |
4 |
A |
$0.87 |
$55,556 |
D/D |
64,027 |
237,473 |
|
- |
|
| Schreiber Taylor |
Chief Executive Officer |
• • – |
2025-08-25 |
4 |
A |
$0.87 |
$22,222 |
D/D |
25,610 |
96,612 |
|
- |
|
| Stout Stephen |
See Remarks |
• – – |
2025-08-25 |
4 |
A |
$0.87 |
$11,111 |
D/D |
12,805 |
86,275 |
|
- |
|
| Shukla Abhinav A. |
Chief Technical Officer |
• – – |
2025-08-25 |
4 |
A |
$0.87 |
$4,444 |
D/D |
5,122 |
81,258 |
|
- |
|
| Siegall Clay B |
|
– • – |
2025-08-25 |
4 |
A |
$0.87 |
$111,112 |
D/D |
128,054 |
128,054 |
|
- |
|
| Deyoung Casi |
Chief Business Officer |
• – – |
2025-01-25 |
4 |
D |
$1.16 |
$2,665 |
D/D |
(2,297) |
81,465 |
|
- |
|
| Shukla Abhinav A. |
Chief Technical Officer |
• – – |
2025-01-25 |
4 |
D |
$1.16 |
$2,623 |
D/D |
(2,261) |
73,536 |
|
- |
|
| Pandite Arundathy N. |
Chief Medical Officer |
• – – |
2025-01-25 |
4 |
D |
$1.16 |
$3,725 |
D/D |
(3,211) |
206,265 |
|
- |
|
| Pandite Arundathy N. |
Chief Medical Officer |
• – – |
2025-01-10 |
4 |
D |
$1.19 |
$8,192 |
D/D |
(6,884) |
209,476 |
|
- |
|
| Shukla Abhinav A. |
Chief Technical Officer |
• – – |
2025-01-10 |
4 |
D |
$1.19 |
$5,748 |
D/D |
(4,830) |
74,597 |
|
- |
|
| Deyoung Casi |
Chief Business Officer |
• – – |
2025-01-10 |
4 |
D |
$1.19 |
$6,815 |
D/D |
(5,727) |
83,762 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-04 |
4 |
A |
$1.25 |
$1,283,610 |
I/I |
1,026,888 |
5,539,724 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-04 |
4 |
D |
$1.25 |
$1,283,610 |
I/I |
(1,026,888) |
4,512,836 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-04 |
4 |
B |
$1.25 |
$166,714 |
I/I |
133,371 |
5,539,724 |
2.25 |
- |
|
| Green Jeremy |
Director |
– • • |
2024-12-04 |
4 |
S |
$1.25 |
$166,714 |
I/I |
(133,371) |
5,406,353 |
|
- |
|
| Schreiber Taylor |
Chief Executive Officer |
• • – |
2024-10-07 |
4 |
B |
$1.21 |
$44,220 |
D/D |
36,500 |
71,002 |
0.01 |
- |
|
| Brous Tyler |
|
– • – |
2024-06-28 |
4 |
B |
$3.90 |
$11,700 |
D/D |
3,000 |
238,088 |
0.01 |
- |
|
| Brous Tyler |
|
– • – |
2024-06-27 |
4 |
B |
$3.89 |
$21,068 |
D/D |
5,416 |
235,088 |
0.01 |
- |
|
| Schreiber Taylor |
Chief Executive Officer |
• • – |
2024-06-26 |
4 |
B |
$3.47 |
$50,011 |
D/D |
14,400 |
34,502 |
0.01 |
- |
|
| Schreiber Taylor |
Chief Executive Officer |
• • – |
2024-06-04 |
4 |
OE |
$3.57 |
$10,889 |
D/D |
3,050 |
20,102 |
|
- |
|
| Stout Stephen |
See Remarks |
• – – |
2024-05-10 |
4 |
D |
$10.42 |
$10,076 |
D/D |
(967) |
73,470 |
|
- |
|
| Green Jeremy |
Director |
– • • |
2024-03-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,425) |
5,615,489 |
|
- |
|
| Stout Stephen |
See Remarks |
• – – |
2024-03-06 |
4 |
AS |
$10.53 |
$168,522 |
D/D |
(16,004) |
74,437 |
|
- |
|
156 Records found
|
|
Page 1 of 7 |
|
|
